search
Back to results

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

Primary Purpose

Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
aflibercept 8 mg PFS
Sponsored by
Regeneron Pharmaceuticals
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetic Macular Edema (DME) focused on measuring Neovascular "wet" age-related macular degeneration

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria: Patient must have diabetic macular edema (DME) or neovascular "wet" age-related macular degeneration (nAMD) in the study eye Study eye considered by the retina specialist to be eligible for treatment with 8 mg aflibercept Key Exclusion Criteria: Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past IVT injections with any agent in either eye Treatment with any IVT injection in the study eye within the 25 days prior to day 1 Intraocular pressure (IOP) >25 mm Hg in the study eye at screening Any intraocular surgery in the study eye at any time during the past 3 months Any prior extended-release therapeutic agent, or ocular drug-release device implantation (approved or investigational, including steroids) in the study eye NOTE: Other protocol Defined Inclusion/Exclusion Criteria Apply

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    8 mg Dose

    Arm Description

    Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.

    Outcomes

    Primary Outcome Measures

    Number of 8 mg aflibercept injections successfully administered utilizing the PFS
    Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.

    Secondary Outcome Measures

    Incidence of ocular adverse events (AEs) in the study eye
    Incidence of ocular severe adverse events (SAEs) in the study eye

    Full Information

    First Posted
    August 3, 2023
    Last Updated
    August 3, 2023
    Sponsor
    Regeneron Pharmaceuticals
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05989126
    Brief Title
    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
    Official Title
    A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 13, 2023 (Anticipated)
    Primary Completion Date
    January 17, 2024 (Anticipated)
    Study Completion Date
    January 17, 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Regeneron Pharmaceuticals

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Regeneron Pharmaceuticals developed a single-dose glass pre-filled syringe (PFS) to deliver 8 mg aflibercept. The PFS is a convenient device that contains the study medication that will be injected in your study eye. A PFS offers a sterile, single dose of study drug within the syringe; this eliminates the need for the retina specialist to prepare the injection syringe from a separate vial. This Phase IIIb study is focused on patients with diabetic macular edema (DME) and neovascular (wet) age-related macular degeneration (nAMD). The main aim of the study is to evaluate if the 8 mg aflibercept PFS allows for successful preparation and administration of 8 mg aflibercept by retina specialists. The study will also assess the safety of 8 mg aflibercept PFS use. Regeneron will use the information from the study to better understand if the PFS can be used safely and effectively by retina specialists to administer 8 mg aflibercept.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Diabetic Macular Edema (DME), Neovascular Age-Related Macular Degeneration (nAMD)
    Keywords
    Neovascular "wet" age-related macular degeneration

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    35 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    8 mg Dose
    Arm Type
    Experimental
    Arm Description
    Only 1 eye will be selected as the study eye by the investigator. Patients will receive a single dose utilizing the PFS.
    Intervention Type
    Drug
    Intervention Name(s)
    aflibercept 8 mg PFS
    Other Intervention Name(s)
    EYLEA ®, BAY86-5321
    Intervention Description
    Sterile aqueous solution in a single-dose glass PFS administered by intravitreal (IVT) injection
    Primary Outcome Measure Information:
    Title
    Number of 8 mg aflibercept injections successfully administered utilizing the PFS
    Description
    Participants received a single dose of study drug, administered in the selected study eye with the PFS by a retina specialist. Physician assessed successful aflibercept preparation and administration with the PFS.
    Time Frame
    At Day 1
    Secondary Outcome Measure Information:
    Title
    Incidence of ocular adverse events (AEs) in the study eye
    Time Frame
    Through Day 29
    Title
    Incidence of ocular severe adverse events (SAEs) in the study eye
    Time Frame
    Through Day 29

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Key Inclusion Criteria: Patient must have diabetic macular edema (DME) or neovascular "wet" age-related macular degeneration (nAMD) in the study eye Study eye considered by the retina specialist to be eligible for treatment with 8 mg aflibercept Key Exclusion Criteria: Any active intraocular inflammation or infection in either eye or history of intraocular inflammation or infection after past IVT injections with any agent in either eye Treatment with any IVT injection in the study eye within the 25 days prior to day 1 Intraocular pressure (IOP) >25 mm Hg in the study eye at screening Any intraocular surgery in the study eye at any time during the past 3 months Any prior extended-release therapeutic agent, or ocular drug-release device implantation (approved or investigational, including steroids) in the study eye NOTE: Other protocol Defined Inclusion/Exclusion Criteria Apply
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Clinical Trials Administrator
    Phone
    844-734-6643
    Email
    clinicaltrials@regeneron.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Clinical Trial Management
    Organizational Affiliation
    Regeneron Pharmaceuticals
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Yes
    IPD Sharing Plan Description
    All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
    IPD Sharing Time Frame
    When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.
    IPD Sharing Access Criteria
    Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
    IPD Sharing URL
    https://vivli.org/

    Learn more about this trial

    Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

    We'll reach out to this number within 24 hrs